One promising strategy to explore HDAC inhibitor-mediated down-regulation of HIFs for targeting TP53 mutant tumor resistance to antiangiogenic therapy is supported by both preclinical and retrospective clinical findings20–27. Here, HDAC9 is linked to neoplasm.